Cleerly Announces New Findings on How AI-QCT Plaque Measurements Relate to Long-Term Cardiovascular Risk
New ESC Congress 2026 data, published simultaneously in EJNMMI, show that AI-quantified plaque burden was independently associated with...
Cleerly and Allelica Partner to Launch a Polygenic Risk Score Test for Coronary Artery Disease
The Cleerly Polygenic Cardiovascular Risk Score Test, powered by Allelica’s proprietary multi-ancestry PRS technology, gives physicians a new option...
Cleerly to Debut Customizable Full Text Reports and Present New AI-QCT Research at SCCT2026
New Full Text Report Configurability and Six Scientific Presentations at the 21st Annual Scientific Meeting of the Society of Cardiovascular Computed...
MemorialCare Heart & Vascular Institute Becomes First Hospital in Los Angeles County to Offer Cleerly AI-Powered Heart Disease Analysis, Quantifying Total Plaque Volume and Soft Plaque
Systemwide launch brings AI powered assessment to Coronary CTA’s to MemorialCare’s Long Beach Medical Center, Orange Coast Medical Center, and...
